Vistagen Reports Fiscal 2024 Third Quarter Financial Results

Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on trackPALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stag...

Related Keywords

United States , Shawn Singh , Marka Mcpartland , Company Phase , Company Quarterly Report On Form , International Number Toll , Women Health Indications , Exchange Commission , Chief Executive Officer , Nasal Spray , Acute Treatment , Social Anxiety Disorder , Subjective Units , Distress Scale , Drug Application , Major Depressive Disorder , Vasomotor Symptoms , Hot Flashes , Quarter Financial , Dial In Number , Annual Report , Quarterly Report ,